SCHEMBL1102865

SCHEMBL1102865

c1ccc2c(-c3c4ccccc4c(-c4cccc5ccccc45)c4ncccc34)cccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
MAPT P10636 4/20 0.47
CCR1 P32246 4/20 0.47
CCR8 P51685 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CYP3A4 P08684 2/20 0.47
TP53 P04637 2/20 0.47
LMNA P02545 2/20 0.47
MMP2 P08253 2/20 0.47
TSHR P16473 2/20 0.47
CCR5 P51681 2/20 0.47
GMNN O75496 1/20 0.47
HSP90AA1 P07900 1/20 0.47
CYP2D6 P10635 1/20 0.47
MMP9 P14780 1/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
MMP8 P22894 1/20 0.47
THPO P40225 1/20 0.47
MTOR P42345 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103090 0.98 KDM4E (0.45) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL13512523 0.96 KDM4E (0.50) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103195 0.95 KDM4E (0.43) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1102970 0.93 KDM4E (0.44) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103197 0.91 TNF (0.43) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103215 0.91 CCR1 (0.47) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103187 0.91 TNF (0.46) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103232 0.91 ALDH1A1 (0.40) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103088 0.91 KDM4E (0.40) KDM4EMAPTCCR1CCR8SMN1; SMN2
SCHEMBL1103193 0.91 CYP11B1 (0.42) KDM4EMAPTCCR1CCR8SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885MAPT 3162/4885CCR1 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.